MGX (Metagenomi) EPS (Basic) : $-2.11 (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi EPS (Basic)?

Metagenomi's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.68. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.11.

Metagenomi's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.68. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.11.

Metagenomi's EPS without NRI for the three months ended in Mar. 2025 was $-0.68. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -1.88.

During the past 3 years, the average EPS without NRI Growth Rate was -37.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Metagenomi's highest 3-Year average EPS without NRI Growth Rate was -37.50% per year. The lowest was -37.50% per year. And the median was -37.50% per year.

Metagenomi EPS (Basic) Historical Data

The historical data trend for Metagenomi's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi EPS (Basic) Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

-0.72

-1.46

-1.82

-2.36

Metagenomi Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial							-1.19	-0.29	-0.51	-0.63	-0.68

Metagenomi EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Metagenomi's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-78.058	-	0)	/	33.028
	=	-2.36

Metagenomi's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-25.039	-	0)	/	37.019
	=	-0.68

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.11

Metagenomi (NAS:MGX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Metagenomi EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Metagenomi's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608

Website

https://metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.